-
BioForward 2018: Growing Life Science in Birmingham
Sciad Communications joins OBN for the inaugural BioForward 2018 Conference The Sciad team headed to Birmingham last week for OBN’s new event, BioForward. The event was the first ‘Roadmap for Growth’ life sciences event hosted by OBN and focussed on helping early stage, emerging, and developing life sciences companies maximise their chances of success. It was a…
-
Pharma Integrates 2018: 12–13 November
London, UK, 9th October 2018 / Sciad Newswire / Following the success of last year’s event, Pharma Integrates 2018 will take place in London on the 12th and 13th of November at the Grange Tower Bridge Hotel. With an elite faculty of distinguished and influential speakers, and an interactive debate-led format that promotes the exchange of both practical and theoretical knowledge between the panellists…
-
Solentim Wins Two Queen’s Awards for Enterprise
Wimborne, UK, 8th October 2018 / Sciad Newswire / Solentim, a leading provider of instrumentation used by biopharma companies in the fields of mammalian cell line development and cell culture, has received two Queen’s Awards for Enterprise, one for International Trade and one for Innovation. The Queen’s Awards for Enterprise are the UK’s most prestigious business awards,…
-
Riffyn launches Open Access for scientists at non-profits
To celebrate the ground-breaking publication of Riffyn SDE in the journal Scientific Data, Riffyn is launching Open Access which provides free use of the SDE for next-generation design and publishing of experiments Oakland, CA, USA, 3rd October 2018 / Sciad Newswire / Riffyn, a global provider of cloud-based experiment design and data analytics software, has launched Riffyn Open Access which provides…
-
Innovate UK Awards Medherant a Medicines Manufacturing Grant
New funding to support manufacture of transdermal patches for clinical trials Coventry, UK, 3rd October 2018 / Sciad Newswire / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK. The grant will enable the Company to buy equipment and move forward with…
-
SynbiCITE launches new five-year strategy
London, UK, 2nd October 2018 / Sciad Newswire / SynbiCITE, the UK’s national centre for commercialisation of synthetic biology, is pleased to announce the launch of a new five-year strategy underpinned by a new £5M grant from UKRI and other sources. The new strategy will see the launch of SynbiCITE 2.0, which aims to expand and develop SynbiCITE’s…
-
New study shows how academics are the driving force in oncology R&D
Talent pipeline struggling to keep up with demand London, UK, 2nd October 2018 / Sciad Newswire / The RSA Group, the leading global Life Sciences executive search firm, has published the latest of its Talent Equity® reports. The new report identifies academia as the driving force in biotech’s fast moving oncology sector with almost half of the sector’s scientific leadership coming…
-
Major international FDA-led study confirms CellOPTIQ® High Content Assay as leading in vitro platform to assess cardiotoxicity in new drugs
Motherwell, Scotland, 27th September 2018 / Sciad Newswire / Clyde Biosciences, the leader in cardiac cell function assessment, announced today that its proprietary CellOPTIQ® High Content Assay (HCA) outperformed other assay types in the global CiPA myocyte study designed to develop more accurate and comprehensive in vitro cardiac safety evaluation of new drugs. CiPA (the ‘Comprehensive in vitro Proarrhythmia Assay’) is a global…
-
Domainex appoints Dr Trevor Perrior as Chief Executive Officer
Cambridge, UK, 20th September 2018 / Sciad Newswire / Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018. Dr Perrior has held the position of Director of Research and Chief Scientific Officer at Domainex since 2005. The company has grown significantly…
-
Identification of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent HCV activity, published in The Journal of Medicinal Chemistry
Discovery follows successful collaboration between Selcia, Cypralis and Gilead Sciences Cambridge and Ongar, UK, 17th September 2018 / Sciad Newswire / A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal…